DE60220157D1 - Verfahren zur modulierung der proliferation von medullären schilddrüsen-karzinomzellen - Google Patents

Verfahren zur modulierung der proliferation von medullären schilddrüsen-karzinomzellen

Info

Publication number
DE60220157D1
DE60220157D1 DE60220157T DE60220157T DE60220157D1 DE 60220157 D1 DE60220157 D1 DE 60220157D1 DE 60220157 T DE60220157 T DE 60220157T DE 60220157 T DE60220157 T DE 60220157T DE 60220157 D1 DE60220157 D1 DE 60220157D1
Authority
DE
Germany
Prior art keywords
cys
proliferation
modulating
carcinoma cells
thyroid carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60220157T
Other languages
English (en)
Other versions
DE60220157T2 (de
Inventor
Uberti Ettore Ciro Degli
Maria Chiara Zatelli
Michael Dewitt Culler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita Degli Studi Di Ferrara Ferrara It
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
IL CONSORZIO FERRARA RICHERCHE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS, IL CONSORZIO FERRARA RICHERCHE filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Application granted granted Critical
Publication of DE60220157D1 publication Critical patent/DE60220157D1/de
Publication of DE60220157T2 publication Critical patent/DE60220157T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60220157T 2001-03-06 2002-03-06 Verfahren zur modulierung der proliferation von medullären schilddrüsen-karzinomzellen Expired - Lifetime DE60220157T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27369901P 2001-03-06 2001-03-06
US273699P 2001-03-06
PCT/US2002/006729 WO2002070555A2 (en) 2001-03-06 2002-03-06 Method of modulating the proliferation of medullary thyroid carcinoma cells

Publications (2)

Publication Number Publication Date
DE60220157D1 true DE60220157D1 (de) 2007-06-28
DE60220157T2 DE60220157T2 (de) 2008-01-17

Family

ID=23045039

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60236225T Expired - Lifetime DE60236225D1 (de) 2001-03-06 2002-03-06 Verfahren zur Modulation der Proliferation von Schilddrüsenkrebszellen
DE60220157T Expired - Lifetime DE60220157T2 (de) 2001-03-06 2002-03-06 Verfahren zur modulierung der proliferation von medullären schilddrüsen-karzinomzellen
DE60232203T Expired - Lifetime DE60232203D1 (de) 2001-03-06 2002-03-06 Verfahren zur Modulation der Proliferation von Schilddrüsenkrebszellen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60236225T Expired - Lifetime DE60236225D1 (de) 2001-03-06 2002-03-06 Verfahren zur Modulation der Proliferation von Schilddrüsenkrebszellen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60232203T Expired - Lifetime DE60232203D1 (de) 2001-03-06 2002-03-06 Verfahren zur Modulation der Proliferation von Schilddrüsenkrebszellen

Country Status (10)

Country Link
US (3) US20050124549A1 (de)
EP (3) EP1390406B1 (de)
JP (2) JP4294959B2 (de)
AT (3) ATE430162T1 (de)
CA (2) CA2743731C (de)
DE (3) DE60236225D1 (de)
ES (3) ES2345280T3 (de)
NO (1) NO20033881L (de)
RU (3) RU2352578C2 (de)
WO (1) WO2002070555A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262229B1 (en) * 1996-12-04 2001-07-17 Biomeasure Incorporated Somatostatin antagonists
CA2743731C (en) * 2001-03-06 2014-05-06 The Administrators Of The Tulane Educational Fund Method of modulating the proliferation of medullary thyroid carcinoma cells
EP1372688B1 (de) * 2001-03-08 2008-05-07 The Administrators of The Tulane Educational Fund Somatostatin-antagonisten
EP1522311A1 (de) * 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verwendung von Somatostatin oder seine Derivate zur Herstellung eines Medikamentes zur Regulierung der Ovarialfollikelnreserve bei der nicht menopausierte Frau
GB0602639D0 (en) 2006-02-09 2006-03-22 Novartis Ag Organic compounds
EP2003967B1 (de) 2006-03-23 2011-09-07 Ipsen Pharma Verwendung von somatostatin-agonisten zur behandlung von medullärem schilddrüsenkarzinom
EP2835136A1 (de) 2013-08-07 2015-02-11 PregLem S.A. Somatostatin Receptor Modulator zur Unfruchtbarkeitsbehandlung

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661472A (en) * 1985-05-09 1987-04-28 The Salk Institute For Biological Studies GnRH antagonists IX
PT1288223E (pt) 1993-08-09 2005-03-31 Sod Conseils Rech Applic Derivados de peptidos terapeuticos
US5597894A (en) * 1995-06-05 1997-01-28 The Louisiana State University Medical Center Foundation Multi-tyrosinated somatostatin analogs
DE69812084T2 (de) 1997-05-01 2003-12-24 Cedars Sinai Medical Center Verfahren zur behandlung von hyperprolaktinämia und prolaktinomen
US5972893A (en) * 1997-05-06 1999-10-26 Cedars-Sinai Medical Center Method of treating hyperprolactinemia and prolactinomas
US6180082B1 (en) * 1997-11-24 2001-01-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method to enhance tissue accumulation of radiolabeled compounds
CN1250361A (zh) 1997-11-24 2000-04-12 路易斯安那州州立大学及农业机械学院管理委员会 提高放射性标记化合物的组织积累的方法
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
PL346361A1 (en) 1998-07-30 2002-02-11 Sod Conseils Rech Applic Methods of using a somatostatin analogue
HUP0201696A3 (en) * 1999-06-25 2002-10-28 Sod Conseils Rech Applic Cyclic peptides, pharmaceutical compositions comprising thereof and their use
CA2743731C (en) * 2001-03-06 2014-05-06 The Administrators Of The Tulane Educational Fund Method of modulating the proliferation of medullary thyroid carcinoma cells

Also Published As

Publication number Publication date
US20110183416A1 (en) 2011-07-28
RU2317824C2 (ru) 2008-02-27
US20050124549A1 (en) 2005-06-09
JP2007145854A (ja) 2007-06-14
JP4294959B2 (ja) 2009-07-15
EP1897889A2 (de) 2008-03-12
NO20033881L (no) 2003-10-10
US9220760B2 (en) 2015-12-29
WO2002070555A3 (en) 2003-12-04
ATE466029T1 (de) 2010-05-15
EP1390406A2 (de) 2004-02-25
US20070259811A1 (en) 2007-11-08
ES2328077T3 (es) 2009-11-06
DE60236225D1 (de) 2010-06-10
DE60220157T2 (de) 2008-01-17
ES2345280T3 (es) 2010-09-20
ES2284859T3 (es) 2007-11-16
EP1897889B1 (de) 2010-04-28
EP1897889A3 (de) 2008-03-26
CA2743731C (en) 2014-05-06
EP1813625A1 (de) 2007-08-01
JP2005506289A (ja) 2005-03-03
CA2440214C (en) 2012-05-22
JP4828438B2 (ja) 2011-11-30
EP1390406B1 (de) 2007-05-16
ATE362489T1 (de) 2007-06-15
CA2743731A1 (en) 2002-09-12
EP1813625B1 (de) 2009-04-29
RU2275934C2 (ru) 2006-05-10
RU2003129515A (ru) 2005-03-27
ATE430162T1 (de) 2009-05-15
RU2005132456A (ru) 2007-04-27
DE60232203D1 (de) 2009-06-10
CA2440214A1 (en) 2002-09-12
WO2002070555A2 (en) 2002-09-12
NO20033881D0 (no) 2003-09-02
RU2007111864A (ru) 2008-10-10
RU2352578C2 (ru) 2009-04-20

Similar Documents

Publication Publication Date Title
YU25497A (sh) Postupak za dobijanje sildenafila
NZ337531A (en) Substituted benzamides as immunomodulator for normalisation of IL-10/IL/12 balance
EA200301100A1 (ru) Новые фталазиноны
HK1025511A1 (en) Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors
DE60220157D1 (de) Verfahren zur modulierung der proliferation von medullären schilddrüsen-karzinomzellen
EA200400806A1 (ru) Способ получения эхинокандиновых соединений
DE60125378D1 (de) Verfahren zur herstellung von 2-aminomethyl-halogen-pyridinen
DE60041001D1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
DE60224884D1 (de) Verfahren zur herstellung von 3, 3', 6, 6'-tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'-tetraalkylen-5, 5'-dihalo-2, 2' biphenolen
PT1206452E (pt) Processo de preparacao de compostos benzoper-hidroisoindole
DE69431824D1 (de) Verfahren zur Herstellung von Schwefelhaltigen Imidazolderivaten und erhaltene Zwischenprodukte
ATE245147T1 (de) Substituierte aminochinazolinon (thion) derivate
MXPA03006057A (es) Proceso para preparar (+) trans-4-p-fluorofenil -3 hidroximetil.
MX9603348A (es) Derivados de disulfuro de amida indano-2-mercaptoacetilica novedosos utiles como inhibidores de encefalinasa.
DE60043228D1 (de) Herstellungsverfahren von 2-cyanopyridinen
DE69416003T2 (de) Kristalline, polymorphische form von (s,s,s)-n-(1-[2-carboxy-3-(n2-mesyllysylamino)propyl]-1-cyclopentylcarbonyl)tyrosin
FI915025A (fi) 8-azabicyklo(3,2,1) oktylalkyltiazolidinoner, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
ATE265854T1 (de) Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs
DE60001298T2 (de) Verfahren zur Herstellung von Omeprazol
DE69025817D1 (de) 3-Keto-HMG-CoA Reduktase-Inhibitoren
YU62302A (sh) Postupak za izradu jedinjenja 2-(4-alkil-1-piperazinil)- benzaldehida i benzilidenila
DE69427100T2 (de) Herstellung von Beta-lactamverbindungen und Zwischenprodukte
EA200101058A1 (ru) Ароматические амиды
UY24274A1 (es) Nuevos azepanes inhibidores de la proteína quinasa

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: IPSEN PHARMA S.A.S., BOULOGNE-BILLANCOURT, FR

Owner name: UNIVERSITA DEGLI STUDI DI FERRARA, FERRARA, IT